Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
P/E ratio for Profound Medical Corp. (PROF)
P/E ratio as of 2023: -6.20
According to Profound Medical Corp.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.20. At the end of 2022 the company had a P/E ratio of -7.74.
P/E ratio history for Profound Medical Corp. from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -6.20 |
| 2022 | -7.74 |
| 2021 | -7.52 |
| 2020 | -16.44 |
| 2019 | -10.59 |
| 2018 | -3.62 |
| 2017 | -4.10 |
| 2016 | -3.42 |
| 2015 | -2.01 |
| 2014 | -0.26 |